PATENT CLAIM ANALYSIS

Application Number: 15869630
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-12
Patent Classification: ["435", "325000"]

Abstract:
The invention provides regimens and methods for the treatment of cancer comprising continuous infusion of coenzyme Q10. The coenzyme Q10 may be administered as a monotherapy, or in combination with an additional agent, such as an anticancer agent, a chemotherapeutic agent, or an anti-angiogenic agent. The coenzyme Q10 may be administered at two or more different rates.

Claim (Index 50):
The method of  claim 1 , wherein the composition comprising coenzyme Q10 is administered by continuous intravenous infusion for about 18 days, and wherein the composition is administered sequentially at a first rate, a second rate, and a third rate wherein:\n (a) the first rate is a highest rate administered during hour 1 of day 1 of the continuous infusion; (b) the second rate is a lowest rate administered during hours 2 to 24 of day 1 the continuous infusion; and (c) the third rate comprises an intermediate rate administered between the first rate and the second rate administered during days 2 to 17 of the continuous infusion.

Metadata:
- Claim Count in Document: 188.0
- Percentile: 86.0
- Lexical Diversity: 1.6
- Patent Class: 435.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14477828', '11434154', '15376243', '14867554', '12467214']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.5565809667711058
- 35 USC 102 Novelty (BERT): 0.6919736136317618
- Combined Prediction Score: 0.5701202314571715
- Mean Citation Score: 365.43693
- Max Citation Score: 703.2847
- Similarity Product: 699.5177717020392

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test